152 results on '"Rye DB"'
Search Results
2. 0653 WORSENING PSYCHOMOTOR VIGILANCE AFTER BRIEF NAPS IN HYPERSOMNOLENT PATIENTS: MSLT NAP CORRELATES
- Author
-
Saini, P, primary, Bremer, EM, additional, Broyles, SS, additional, Rye, DB, additional, and Trotti, L, additional
- Published
- 2017
- Full Text
- View/download PDF
3. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome
- Author
-
Walters, As, Lebrocq, C, Dhar, A, Hening, W, Rosen, R, Allen, Rp, Trenkwalder, C, Adler, C, Newman, S, Reiners, C, Aksu, M, Buchholz, D, Hening, Wa, Anderson, M, Mosko, S, Ancoli-Israel, S, Jimenez, Wb, Hallett, M, Bassetti, C, Clavadetscher, S, Bliwise, Dl, Gurecki, P, Rye, Db, Broch, Ll, Zak, R, Chokroverty, S, Coccagna, G, Lugaresi, E, Miele, F, Montagna, P, Plazzi, G, Provini, F, de Mello MT, Tufik, S, de Weerd AW, Rijsman, Rm, Ehrenberg, B, Eisensehr, I, Ekbom, K, Ljungdahl, A, Garcia-Borreguero, D, Larrosa, O, Hirsch, L, Hogl, B, Horiguchi, J, Hornyak, M, Voderholzer, U, Kryger, M, Skomrow, R, Lipinski, Jf, Masood, A, Phillips, B, Oertel, Wh, Stiasny, K, O'Keeffe, S, Oldani, A, Zucconi, M, Ondo, Wg, Picchietti, D, Poceta, Js, Rich, Gb, Scrima, L, Shafor, R, Sharon, D, Silber, M, Smith, R, Wetter, Tc, Winkelmann, J, Vanek, Z, and Wagner, M
- Subjects
Adult ,medicine.medical_specialty ,Psychometrics ,International Cooperation ,Severity of Illness Index ,03 medical and health sciences ,0302 clinical medicine ,Rating scale ,Restless Legs Syndrome ,mental disorders ,Criterion validity ,Medicine ,Humans ,030212 general & internal medicine ,Restless legs syndrome ,Reliability (statistics) ,Aged ,Aged, 80 and over ,business.industry ,Reproducibility of Results ,General Medicine ,Middle Aged ,medicine.disease ,3. Good health ,Assessment ,Factor analysis ,Psycchometrics ,Reliability ,Validity ,BTBD9 ,Convergent validity ,Case-Control Studies ,Physical therapy ,Clinical Global Impression ,business ,Gabapentin enacarbil ,030217 neurology & neurosurgery ,medicine.drug - Abstract
BACKGROUND There is a need for an easily administered instrument which can be applied to all patients with restless legs syndrome (RLS) to measure disease severity for clinical assessment, research, or therapeutic trials. The pathophysiology of RLS is not clear and no objective measure so far devised can apply to all patients or accurately reflect severity. Moreover, RLS is primarily a subjective disorder. Therefore, a subjective scale is at present the optimal instrument to meet this need. METHODS Twenty centers from six countries participated in an initial reliability and validation study of a rating scale for the severity of RLS designed by the International RLS study group (IRLSSG). A ten-question scale was developed on the basis of repeated expert evaluation of potential items. This scale, the IRLSSG rating scale (IRLS), was administered to 196 RLS patients, most on some medication, and 209 control subjects. RESULTS The IRLS was found to have high levels of internal consistency, inter-examiner reliability, test-retest reliability over a 2-4 week period, and convergent validity. It also demonstrated criterion validity when tested against the current criterion of a clinical global impression and readily discriminated patient from control groups. The scale was dominated by a single severity factor that explained at least 59% of the pooled item variance. CONCLUSIONS This scale meets performance criteria for a brief, patient completed instrument that can be used to assess RLS severity for purposes of clinical assessment, research, or therapeutic trials. It supports a finding that RLS is a relatively uniform disorder in which the severity of the basic symptoms is strongly related to their impact on the patient's life. In future studies, the IRLS should be tested against objective measures of RLS severity and its sensitivity should be studied as RLS severity is systematically manipulated by therapeutic interventions.
- Published
- 2003
4. Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies
- Author
-
Qian, Y, primary, Melikian, HE, additional, Rye, DB, additional, Levey, AI, additional, and Blakely, RD, additional
- Published
- 1995
- Full Text
- View/download PDF
5. Restless abdomen: a phenotypic variant of restless legs syndrome.
- Author
-
Pérez-Díaz H, Iranzo A, Rye DB, Santamaría J, Pérez-Díaz, Hernando, Iranzo, Alex, Rye, David B, and Santamaría, Joan
- Published
- 2011
- Full Text
- View/download PDF
6. A genetic risk factor for periodic limb movements in sleep.
- Author
-
Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, Thorgeirsson TE, Palsson S, Sigmundsson T, Sigurdsson AP, Eiriksdottir I, Soebech E, Bliwise D, Beck JM, Rosen A, Waddy S, Trotti LM, Iranzo A, Thambisetty M, Hardarson GA, and Kristjansson K
- Published
- 2007
7. Prolonged assessment of sleep and daytime sleepiness in unrestrained Macaca mulatta.
- Author
-
Daley JT, Turner RS, Freeman A, Bliwise DL, and Rye DB
- Published
- 2006
8. Quantification of electromyographic activity during sleep: a phasic electromyographic metric.
- Author
-
Bliwise DL, He L, Ansari FP, and Rye DB
- Published
- 2006
- Full Text
- View/download PDF
9. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD.
- Author
-
Iranzo A, Santamaría J, Rye DB, Valldeoriola F, Martí MJ, Muñoz E, Vilaseca I, and Tolosa E
- Published
- 2005
- Full Text
- View/download PDF
10. Brief report. Hemodialysis disrupts basic sleep regulatory mechanisms: building hypotheses.
- Author
-
Parker KP, Bliwise DL, and Rye DB
- Published
- 2000
- Full Text
- View/download PDF
11. What should we be measuring? Defining the 'P' in PLMS.
- Author
-
Rye DB
- Published
- 2006
- Full Text
- View/download PDF
12. Relief in sight for restless legs syndrome.
- Author
-
Rye DB and Rye, David B
- Published
- 2004
- Full Text
- View/download PDF
13. Evidence continues to mount on the relationship of restless legs syndrome/ periodic limb movements in sleep to hypertension, cardiovascular disease, and stroke.
- Author
-
Walters AS and Rye DB
- Published
- 2010
14. The two faces of Eve: dopamine's modulation of wakefulness and sleep.
- Author
-
Rye DB and Rye, David B
- Published
- 2004
- Full Text
- View/download PDF
15. An algorithm for the management of restless legs syndrome.
- Author
-
Silber MH, Ehrenberg BL, Allen RP, Buchfuhrer MJ, Earley CJ, Hening WA, Rye DB, Restless Legs Syndrome Foundation. Medical Advisory Board, Silber, Michael H, Ehrenberg, Bruce L, Allen, Richard P, Buchfuhrer, Mark J, Earley, Christopher J, Hening, Wayne A, Rye, David B, and Medical Advisory Board of the Restless Legs Syndrome Foundation
- Abstract
Restless legs syndrome (RLS) is a common disorder with a prevalence of 5% to 15%. Primary care physicians must become familiar with management of this disorder. This algorithm for the management of RLS was written by members of the Medical Advisory Board of the Restless Legs Syndrome Foundation and is based on scientific evidence and expert opinion. Restless legs syndrome is divided into intermittent, daily, and refractory types. Nonpharmacological approaches, including mental alerting activities, avoiding substances or medications that may exacerbate RLS, and addressing the possibility of iron deficiency, are discussed. The role of carbidopa/levodopa, dopamine agonists, opioids, benzodiazepines, and anticonvulsants for the different types of the disorder is delineated. [ABSTRACT FROM AUTHOR]
- Published
- 2004
16. Validation and performance of the sleep inertia questionnaire in central disorders of hypersomnolence.
- Author
-
Sung ER, Maness CB, Cook JD, Vascan AM, Moron D, Saini P, Rye DB, Plante DT, and Trotti LM
- Subjects
- Humans, Male, Female, Surveys and Questionnaires standards, Adult, Prospective Studies, Middle Aged, Reproducibility of Results, Idiopathic Hypersomnia diagnosis, Disorders of Excessive Somnolence diagnosis, Narcolepsy diagnosis
- Abstract
Background: Optimal measurement tools for problematic sleep inertia, common in some central disorders of hypersomnolence (CDH), have not yet been determined. We evaluated the performance of the Sleep Inertia Questionnaire (SIQ) in CDH, and how well it distinguished hypersomnolent groups from controls, and IH (idiopathic hypersomnia) from narcolepsy type 1 (NT1)., Methods: This prospective, bi-centric study included 63 control, 84 IH, 16 NT1, 18 narcolepsy type 2 (NT2), and 88 subjective excessive daytime sleepiness (sEDS) participants, using ICSD-3 criteria. 126 (47.2 %) participants were on any medication at the time of SIQ completion. We assessed construct validity of SIQ scores, and sleep inertia duration (SID), and compared them across diagnoses, controlling for age and center. We derived cutpoints to distinguish hypersomnolent patients from controls and IH from NT1. Sensitivity analyses for depression, chronotype, and medication were performed., Results: The SIQ sum and composite score were significantly lower in controls than in other groups (p < 0.0001), demonstrating outstanding ability to distinguish patients from controls (AUCs 0.92), without differences among hypersomnolent groups. SID (AUC 0.76) was significantly shorter in controls than in all hypersomnolent groups except NT1, and was shorter in NT1 than in IH or sEDS. Optimal SIQ sum cutpoint was 42 (J = 0.71) for patients versus controls. Optimal SID cutpoint in distinguishing IH from NT1 was 25 min (J = 0.39)., Conclusion: The SIQ has excellent ability to distinguish hypersomnolent patients from healthy controls, after controlling for depression, eveningness, and medication. SID is best at distinguishing IH from NT1., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Lynn Marie Trotti reports financial support was provided by National Institutes of Health. David T. Plante reports financial support was provided by American Academy of Sleep Medicine Foundation. Dr. Lynn Marie Trotti reports a relationship with American Academy of Sleep Medicine Foundation that includes: board membership and funding grants. Lynn Marie Trotti reports a relationship with American Academy of Sleep Medicine that includes: board membership, speaking and lecture fees, and travel reimbursement. Lynn Marie Trotti reports a relationship with American Board of Sleep Medicine that includes: board membership. Lynn Marie Trotti reports a relationship with Sleep Research Society that includes: speaking and lecture fees. Lynn Marie Trotti reports a relationship with CHEST that includes: speaking and lecture fees and travel reimbursement. Lynn Marie Trotti reports a relationship with Haymarket Medical Education that includes: speaking and lecture fees and travel reimbursement. Lynn Marie Trotti reports a relationship with Per CME that includes: speaking and lecture fees and travel reimbursement. Lynn Marie Trotti reports a relationship with Efficient CME that includes: speaking and lecture fees. Lynn Marie Trotti reports a relationship with Clinical Care Options LLC that includes: speaking and lecture fees and travel reimbursement. David T. Plante reports a relationship with National Institutes of Health that includes: funding grants. David T. Plante reports a relationship with Wisconsin Alumni Research Foundation Inc that includes: funding grants. David T. Plante reports a relationship with Harmony Biosciences that includes: consulting or advisory and funding grants. David T. Plante reports a relationship with Alzheimer's Association that includes: funding grants. David T. Plante reports a relationship with Jazz Pharmaceuticals Inc that includes: consulting or advisory. David T. Plante reports a relationship with Aditium Biosci that includes: consulting or advisory. David T. Plante reports a relationship with Alkermes that includes: consulting or advisory. David T. Plante reports a relationship with Teva Pharmaceutical Australia that includes: consulting or advisory. David T. Plante reports a relationship with American Academy of Sleep Medicine that includes: speaking and lecture fees. David Rye reports a relationship with National Institutes of Health that includes: funding grants. David T. Plante reports a relationship with NextSense that includes: funding grants. David Rye reports a relationship with Jazz Pharmaceuticals Inc that includes: consulting or advisory. David Rye reports a relationship with Takeda that includes: consulting or advisory. Ana Maria Vascan reports a relationship with National Institutes of Health that includes: funding grants. Ana Maria Vascan reports a relationship with Wisconsin Alumni Research Foundation Inc that includes: funding grants. Ana Maria Vascan reports a relationship with NASA that includes: funding grants. Prabhjyot Saini reports a relationship with NextSense that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. Royalty from Cambridge University Press to David T. Plante. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
17. Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial.
- Author
-
Trotti LM, Blake T, Hoque R, Rye DB, Sharma S, and Bliwise DL
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Treatment Outcome, Idiopathic Hypersomnia drug therapy, Idiopathic Hypersomnia diagnosis, Severity of Illness Index, Benzhydryl Compounds administration & dosage, Benzhydryl Compounds therapeutic use, Benzhydryl Compounds adverse effects, Benzhydryl Compounds pharmacology, Wakefulness-Promoting Agents therapeutic use, Wakefulness-Promoting Agents administration & dosage, Wakefulness-Promoting Agents pharmacology, Double-Blind Method, Amphetamine administration & dosage, Amphetamine adverse effects, Young Adult, Modafinil administration & dosage, Modafinil therapeutic use, Modafinil pharmacology, Narcolepsy drug therapy, Dextroamphetamine administration & dosage, Dextroamphetamine therapeutic use, Dextroamphetamine adverse effects, Central Nervous System Stimulants administration & dosage, Central Nervous System Stimulants therapeutic use, Central Nervous System Stimulants adverse effects
- Abstract
Background and Objective: Although there are several treatments for narcolepsy type 2 and idiopathic hypersomnia, studies that assess amphetamines, symptoms beyond sleepiness, and comparative effectiveness are needed. We performed a randomized, fully blinded, noninferiority trial of modafinil versus amphetamine-dextroamphetamine in these disorders., Methods: Forty-four adults were randomized to modafinil or amphetamine-dextroamphetamine, individually titrated to a maximum of modafinil 200 mg twice daily or amphetamine-dextroamphetamine 20 mg twice daily, for 12 weeks. Primary outcome was change in Epworth from baseline to week 12, with a noninferiority threshold of 2 points. Secondary outcomes were (1) patient global impression of change measures of disease severity, sleepiness, sleep inertia, and cognition; (2) change from baseline in Hypersomnia Severity Index; and (3) change from baseline in Sleep Inertia Questionnaire. Adverse events were compared between groups., Results: Epworth improved 5.0 [± standard deviation (SD) 2.7] points with modafinil and 4.4 (± SD 4.7) with amphetamine-dextroamphetamine; noninferiority of amphetamine-dextroamphetamine was not demonstrated (P = 0.11). Noninferiority of amphetamine-dextroamphetamine was demonstrated for change scores of severity, sleepiness, sleep inertia, Hypersomnia Severity Index, and Sleep Inertia Questionnaire. Dropouts due to adverse events were 31.8% for modafinil (including two severe events) and 9.1% for amphetamine-dextroamphetamine, P = 0.13. Anxiety was more common with modafinil and appetite suppression with amphetamine-dextroamphetamine., Conclusion: Noninferiority of amphetamine-dextroamphetamine to modafinil was not demonstrated for the primary outcome. However, amphetamine-dextroamphetamine was noninferior on multiple secondary measures of disease severity and symptomatology. These data may inform shared decision-making regarding treatment for idiopathic hypersomnia and narcolepsy type 2., Registration: Clinicaltrials.gov Registration (NCT03772314) 12/10/18. ., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
18. Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction.
- Author
-
Schormair B, Zhao C, Bell S, Didriksen M, Nawaz MS, Schandra N, Stefani A, Högl B, Dauvilliers Y, Bachmann CG, Kemlink D, Sonka K, Paulus W, Trenkwalder C, Oertel WH, Hornyak M, Teder-Laving M, Metspalu A, Hadjigeorgiou GM, Polo O, Fietze I, Ross OA, Wszolek ZK, Ibrahim A, Bergmann M, Kittke V, Harrer P, Dowsett J, Chenini S, Ostrowski SR, Sørensen E, Erikstrup C, Pedersen OB, Topholm Bruun M, Nielsen KR, Butterworth AS, Soranzo N, Ouwehand WH, Roberts DJ, Danesh J, Burchell B, Furlotte NA, Nandakumar P, Earley CJ, Ondo WG, Xiong L, Desautels A, Perola M, Vodicka P, Dina C, Stoll M, Franke A, Lieb W, Stewart AFR, Shah SH, Gieger C, Peters A, Rye DB, Rouleau GA, Berger K, Stefansson H, Ullum H, Stefansson K, Hinds DA, Di Angelantonio E, Oexle K, and Winkelmann J
- Subjects
- Humans, Risk Factors, Female, Male, Polymorphism, Single Nucleotide, Mendelian Randomization Analysis, Machine Learning, Restless Legs Syndrome genetics, Genome-Wide Association Study, Genetic Predisposition to Disease
- Abstract
Restless legs syndrome (RLS) affects up to 10% of older adults. Their healthcare is impeded by delayed diagnosis and insufficient treatment. To advance disease prediction and find new entry points for therapy, we performed meta-analyses of genome-wide association studies in 116,647 individuals with RLS (cases) and 1,546,466 controls of European ancestry. The pooled analysis increased the number of risk loci eightfold to 164, including three on chromosome X. Sex-specific meta-analyses revealed largely overlapping genetic predispositions of the sexes (r
g = 0.96). Locus annotation prioritized druggable genes such as glutamate receptors 1 and 4, and Mendelian randomization indicated RLS as a causal risk factor for diabetes. Machine learning approaches combining genetic and nongenetic information performed best in risk prediction (area under the curve (AUC) = 0.82-0.91). In summary, we identified targets for drug development and repurposing, prioritized potential causal relationships between RLS and relevant comorbidities and risk factors for follow-up and provided evidence that nonlinear interactions are likely relevant to RLS risk prediction., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
19. Restless legs syndrome, periodic limb movements of sleep, and subclinical cardiovascular disease.
- Author
-
Hochstrasser KJ, Rogers SC, Quyyumi A, Johnson D, Pak V, Shah AJ, Rye DB, and Trotti LM
- Abstract
Restless legs syndrome (RLS) and periodic limb movements of sleep (PLMS) have been variably implicated in risk for cardiovascular disease (CVD), but there is lack of consensus on these relationships. We sought to assess subclinical CVD measures and RLS/PLMS in a large cohort to further evaluate these associations. The Emory Center for Health Discovery and Well Being cohort is composed of employed adults, with subclinical CVD measures including endothelial function (flow-mediated vasodilation), microvascular function (reactive hyperemia index, RHI), arterial stiffness (pulse wave velocity and augmentation index), and carotid intima-media thickness (cIMT). Participants were grouped based on presence ( N = 50) or absence ( N = 376) of RLS and subclinical CVD measures compared between groups. A subset of participants ( n = 40) underwent ambulatory monitoring for PLMS and obstructive sleep apnea. PLMS association with subclinical CVD measures was assessed. RLS status was significantly associated with flow-mediated dilation in univariate analyses but not after controlling for potential confounders; RLS was not associated with other subclinical CVD measures. PLMS were significantly correlated with the RHI, augmentation index, and cIMT in univariate analyses; only the association between PLMS and cIMT remained significant ( p = 0.04) after controlling for RLS status, age, apnea-hypopnea index, hyperlipidemia, and hypertension. The observed association between higher PLMS and greater cIMT suggests that PLMS may be a marker of subclinical CVD. Further work is needed to determine the relationship between PLMS and CVD risk., Supplementary Information: The online version contains supplementary material available at 10.1007/s41105-023-00497-7., Competing Interests: Conflict of interestThe authors declare they have no financial conflicts of interest. Dr. Trotti is a member of the Board of Directors of the American Academy of Sleep Medicine (AASM); views expressed are those of the authors and do not necessarily reflect those of the AASM or the funding source (National Institutes of Health)., (© The Author(s), under exclusive licence to Japanese Society of Sleep Research 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
- Published
- 2023
- Full Text
- View/download PDF
20. Feigning daytime sleepiness: potential effects on the psychomotor vigilance test.
- Author
-
Mariano C, Moron D, Maness C, Olvera V, Saini P, Rye DB, Bliwise DL, and Trotti LM
- Subjects
- Humans, Psychomotor Performance, Wakefulness, Disorders of Excessive Somnolence
- Published
- 2023
- Full Text
- View/download PDF
21. Commonly Used Therapeutics Associated with Changes in Arousal Inhibit GABA A R Activation.
- Author
-
Kaplan A, Nash AI, Freeman AAH, Lewicki LG, Rye DB, Trotti LM, Brandt AL, and Jenkins A
- Subjects
- Humans, Allosteric Regulation physiology, gamma-Aminobutyric Acid pharmacology, Arousal, Receptors, GABA-A metabolism, Flumazenil pharmacology
- Abstract
GABA
A receptor-positive modulators are well-known to induce sedation, sleep, and general anesthesia. Conversely, GABAA receptor negative allosteric modulators (GABAA RNAMs) can increase arousal and induce seizures. Motivated by our studies with patients with hypersomnia, and our discovery that two GABAA RNAMs can restore the Excitation/Inhibition (E/I) balance in vitro and arousal in vivo, we chose to screen 11 compounds that have been reported to modulate arousal, to see if they shared a GABA-related mechanism. We determined modulation with both conventional and microfluidic patch clamp methods. We found that receptor activation was variably modulated by all 11 compounds: Rifampicin (RIF), Metronidazole (MET), Minocycline (MIN), Erythromycin (ERY), Ofloxacin (OFX), Chloroquine (CQ), Hydroxychloroquine sulfate (HCQ), Flumazenil (FLZ), Pentylenetetrazol (PTZ), (-)-Epigallocatechin Gallate (EGCG), and clarithromycin (CLR). The computational modeling of modulator-receptor interactions predicted drug action at canonical binding sites and novel orphan sites on the receptor. Our findings suggest that multiple avenues of investigation are now open to investigate large and brain-penetrant molecules for the treatment of patients with diminished CNS E/I balance.- Published
- 2023
- Full Text
- View/download PDF
22. The Psychomotor Vigilance Test as a measure of alertness and sleep inertia in people with central disorders of hypersomnolence.
- Author
-
Trotti LM, Saini P, Bremer E, Mariano C, Moron D, Rye DB, and Bliwise DL
- Subjects
- Humans, Psychomotor Performance physiology, Sleep, Wakefulness physiology, Disorders of Excessive Somnolence complications, Disorders of Excessive Somnolence diagnosis, Idiopathic Hypersomnia, Narcolepsy diagnosis
- Abstract
Study Objectives: The central disorders of hypersomnolence (CDH) manifest with daytime sleepiness, often accompanied by cognitive symptoms. Objective tests characterizing cognitive dysfunction may have diagnostic utility. Further, because some people with CDH report worsening cognition upon awakening, cognitive testing before and after napping may provide additional diagnostic information., Methods: Patients with CDH with idiopathic hypersomnia (n = 76), narcolepsy type 1 (n = 19), narcolepsy type 2 (n = 22), and self-reported excessive daytime sleepiness not meeting current diagnostic criteria (n = 76) and nonsleepy controls (n = 33) underwent testing with the Psychomotor Vigilance Test (PVT), a 10-minute reaction-time test. A subset of participants underwent repeat testing during a Multiple Sleep Latency Test, before and immediately after naps 2 and 4., Results: Most PVT metrics were significantly better in controls than in patients with CDH. Minimal group differences in PVT performance were observed by CDH diagnosis. PVT performance was weakly correlated to Epworth Sleepiness Scale and Multiple Sleep Latency Test mean sleep latency in the CDH group. Before and after naps, PVT metrics were minimally different for controls, while PVT performance generally worsened following naps in the CDH group, with significant worsening compared with controls for nap 2 mean, median, lapses, and fastest 10% of responses and nap 4 lapses and slowest 10% of responses. Change in performance did not differ based on CDH diagnostic group for any metric on either nap., Conclusions: The PVT, at baseline and following a short nap, may provide adjunctive diagnostic utility in separating individuals with CDH from controls., Citation: Trotti LM, Saini P, Bremer E, et al. The Psychomotor Vigilance Test as a measure of alertness and sleep inertia in people with central disorders of hypersomnolence. J Clin Sleep Med . 2022;18(5):1395-1403., (© 2022 American Academy of Sleep Medicine.)
- Published
- 2022
- Full Text
- View/download PDF
23. Regional brain metabolism differs between narcolepsy type 1 and idiopathic hypersomnia.
- Author
-
Trotti LM, Saini P, Crosson B, Meltzer CC, Rye DB, and Nye JA
- Subjects
- Adult, Brain diagnostic imaging, Female, Humans, Male, Sleep, Disorders of Excessive Somnolence diagnostic imaging, Idiopathic Hypersomnia diagnostic imaging, Narcolepsy diagnostic imaging
- Abstract
Study Objectives: Daytime sleepiness is a manifestation of multiple sleep and neurologic disorders. Few studies have assessed patterns of regional brain metabolism across different disorders of excessive daytime sleepiness. One such disorder, idiopathic hypersomnia (IH), is particularly understudied., Methods: People with IH, narcolepsy (NT1), and non-sleepy controls underwent [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) with electroencephalography (EEG). Participants were instructed to resist sleep and were awoken if sleep occurred. Voxel-wise parametric analysis identified clusters that significantly differed between each pair of groups, with a minimum cluster size of 100 voxels at a cluster detection threshold of p < 0.005. Correlations between glucose metabolism and sleep characteristics were evaluated., Results: Participants (77% women) had IH (n = 16), NT1 (n = 14), or were non-sleepy controls (n = 9), whose average age was 33.8 (±10.7) years. Compared to controls, NT1 participants demonstrated hypermetabolism in fusiform gyrus, middle occipital gyrus, superior and middle temporal gyri, insula, cuneus, precuneus, pre- and post-central gyri, and culmen. Compared to controls, IH participants also demonstrated hypermetabolism in precuneus, inferior parietal lobule, superior and middle temporal gyri, and culmen. Additionally, IH participants demonstrated altered metabolism of the posterior cingulate. Most participants fell asleep. Minutes of N1 during uptake was significantly negatively correlated with metabolism of the middle temporal gyrus., Conclusion: NT1 and IH demonstrate somewhat overlapping, but distinct, patterns of regional metabolism., (© Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
24. Cerebrospinal Fluid Hypocretin and Nightmares in Dementia Syndromes.
- Author
-
Trotti LM, Bliwise DL, Keating GL, Rye DB, and Hu WT
- Abstract
Background/aims: Hypocretin promotes wakefulness and modulates REM sleep. Alterations in the hypocretin system are increasingly implicated in dementia. We evaluated relationships among hypocretin, dementia biomarkers, and sleep symptoms in elderly participants, most of whom had dementia., Methods: One-hundred twenty-six adults (mean age 66.2 ± 8.4 years) were recruited from the Emory Cognitive Clinic. Diagnoses were Alzheimer disease (AD; n = 60), frontotemporal dementia (FTD; n = 21), and dementia with Lewy bodies (DLB; n = 20). We also included cognitively normal controls ( n = 25). Participants and/or caregivers completed sleep questionnaires and lumbar puncture was performed for cerebrospinal fluid (CSF) assessments., Results: Except for sleepiness (worst in DLB) and nocturia (worse in DLB and FTD) sleep symptoms did not differ by diagnosis. CSF hypocretin concentrations were available for 87 participants and normal in 70, intermediate in 16, and low in 1. Hypocretin levels did not differ by diagnosis. Hypocretin levels correlated with CSF total τ levels only in men ( r = 0.34; p = 0.02). Lower hypocretin levels were related to frequency of nightmares (203.9 ± 29.8 pg/mL in those with frequent nightmares vs. 240.4 ± 46.1 pg/mL in those without; p = 0.05) and vivid dreams (209.1 ± 28.3 vs. 239.5 ± 47.8 pg/mL; p = 0.014). Cholinesterase inhibitor use was not associated with nightmares or vivid dreaming., Conclusion: Hypocretin levels did not distinguish between dementia syndromes. Disturbing dreams in dementia patients may be related to lower hypocretin concentrations in CSF., Competing Interests: Dr. Lynn Marie Trotti reports grants from NINDS/NIH during the conduction of this study and personal fees from Medscape and Oakstone for providing CME lectures. Dr. Donald L. Bliwise reports grants from the Alzheimer's Association during the conduction of this study and personal fees from Merck, Ferring, Eisai, and Jazz outside of the submitted work. Dr. Glenda L. Keating has no conflict of interests to declare. Dr. David B. Rye reports grants from NIH/NINDS during the conduction of this study and personal fees from Jazz, Harmony, and Eisai outside of the submitted work. In addition, Dr. David B. Rye has a patent (US9616070B2) issued and licensed to Balance Therapeutics and a patent (US10029-053W01) pending and licensed to Balance Therapeutics and Expansion Therapeutics. Dr. William T. Hu reports grant funding from NINDS/NIH during the conduction of this study and grants from Fujirebio US, personal fees from ViveBio LLC, Roche Diagnostics, and AARP, and nonfinancial support from Advanced Brain Monitoring outside of the submitted work. In addition, Dr. William T. Hu has a patent (US9618522B2) issued., (Copyright © 2021 by S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
25. Sleep/Wake Behavior and EEG Signatures of the TgF344-AD Rat Model at the Prodromal Stage.
- Author
-
Kreuzer M, Keating GL, Fenzl T, Härtner L, Sinon CG, Hajjar I, Ciavatta V, Rye DB, and García PS
- Subjects
- Animals, Area Under Curve, Biomarkers, Female, Male, Models, Animal, Rats, Rats, Transgenic, Sleep Stages, Electroencephalography, Prodromal Symptoms, Sleep, Wakefulness
- Abstract
Transgenic modification of the two most common genes (APPsw, PS1ΔE9) related to familial Alzheimer's disease (AD) in rats has produced a rodent model that develops pathognomonic signs of AD without genetic tau-protein modification. We used 17-month-old AD rats ( n = 8) and age-matched controls (AC, n = 7) to evaluate differences in sleep behavior and EEG features during wakefulness (WAKE), non-rapid eye movement sleep (NREM), and rapid eye movement sleep (REM) over 24-h EEG recording (12:12h dark-light cycle). We discovered that AD rats had more sleep-wake transitions and an increased probability of shorter REM and NREM bouts. AD rats also expressed a more uniform distribution of the relative spectral power. Through analysis of information content in the EEG using entropy of difference, AD animals demonstrated less EEG information during WAKE, but more information during NREM. This seems to indicate a limited range of changes in EEG activity that could be caused by an AD-induced change in inhibitory network function as reflected by increased GABAAR-β2 expression but no increase in GAD-67 in AD animals. In conclusion, this transgenic rat model of Alzheimer's disease demonstrates less obvious EEG features of WAKE during wakefulness and less canonical features of sleep during sleep.
- Published
- 2020
- Full Text
- View/download PDF
26. Large genome-wide association study identifies three novel risk variants for restless legs syndrome.
- Author
-
Didriksen M, Nawaz MS, Dowsett J, Bell S, Erikstrup C, Pedersen OB, Sørensen E, Jennum PJ, Burgdorf KS, Burchell B, Butterworth AS, Soranzo N, Rye DB, Trotti LM, Saini P, Stefansdottir L, Magnusson SH, Thorleifsson G, Sigmundsson T, Sigurdsson AP, Van Den Hurk K, Quee F, Tanck MWT, Ouwehand WH, Roberts DJ, Earley EJ, Busch MP, Mast AE, Page GP, Danesh J, Di Angelantonio E, Stefansson H, Ullum H, and Stefansson K
- Subjects
- Adult, Aged, Genome-Wide Association Study, Humans, Linkage Disequilibrium, Middle Aged, Genetic Predisposition to Disease epidemiology, Genetic Predisposition to Disease genetics, Polymorphism, Single Nucleotide genetics, Restless Legs Syndrome epidemiology, Restless Legs Syndrome genetics
- Abstract
Restless legs syndrome (RLS) is a common neurological sensorimotor disorder often described as an unpleasant sensation associated with an urge to move the legs. Here we report findings from a meta-analysis of genome-wide association studies of RLS including 480,982 Caucasians (cases = 10,257) and a follow up sample of 24,977 (cases = 6,651). We confirm 19 of the 20 previously reported RLS sequence variants at 19 loci and report three novel RLS associations; rs112716420-G (OR = 1.25, P = 1.5 × 10
-18 ), rs10068599-T (OR = 1.09, P = 6.9 × 10-10 ) and rs10769894-A (OR = 0.90, P = 9.4 × 10-14 ). At four of the 22 RLS loci, cis-eQTL analysis indicates a causal impact on gene expression. Through polygenic risk score for RLS we extended prior epidemiological findings implicating obesity, smoking and high alcohol intake as risk factors for RLS. To improve our understanding, with the purpose of seeking better treatments, more genetics studies yielding deeper insights into the disease biology are needed.- Published
- 2020
- Full Text
- View/download PDF
27. TOX3 gene variant could be associated with painful restless legs.
- Author
-
Karroum EG, Saini PS, Trotti LM, and Rye DB
- Subjects
- Alleles, Female, Genotype, Humans, Male, Middle Aged, Apoptosis Regulatory Proteins genetics, Genetic Predisposition to Disease, Genome-Wide Association Study, Pain complications, Restless Legs Syndrome genetics, Trans-Activators genetics
- Abstract
Background/objective: Restless legs syndrome (RLS) is a neurological disorder with a strong genetic susceptibility. A painful RLS sub-phenotype has been described previously but the neurobiological basis for this phenotypic variant remains unknown. This study investigated whether any of the six initially discovered genomic loci associating with RLS (BTBD9, MEIS1, PTPRD, MAP2K5/SKOR1, TOX3, and an intergenic region on chromosome 2), were more strongly associated with complaints of painful versus non-painful RLS., Methods: RLS patients (N = 199; Age = 53.1 ± 16.8; 100% Caucasians; 57% women) diagnosed clinically were genotyped for known variants associating with RLS. Definition of painful RLS required that subjects selected "painful" from a list of 14 adjectives to describe their RLS sensory experience and answered positively to a separate question that queried specifically as to whether they perceived their RLS sensations as painful. Genotype association tests employed logistic regression analyses with assumption of an additive genetic model. Analyses were performed using PLINK software v1.07., Results: We identified two RLS patient subgroups: a painful (n = 41) and non-painful (n = 158). Among 10 tested SNPs, only rs3104767 (related to the TOX3 gene locus) was more associated with painful RLS. The minor allele T of SNP rs3104767 was associated with an increased risk of RLS being perceived as painful with an OR of 1.67 [CI = (1.01-2.74); p = 0.049]. Notably, this minor T allele associated with pain sensation in RLS patients in this study was the non-risk allele for RLS in the original RLS genome wide association study, but a similar trend was observed in a recent Parkinson disease sample study., Conclusion: This study might suggest the TOX3 gene variant as a potential genetic substrate for the painful RLS sub-phenotype. This was an exploratory small study and correction for multiple comparisons would have rendered the results not significant. Therefore, the above findings require replication in larger clinical as well as population-based samples of RLS subjects., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
28. Focus on the pedunculopontine nucleus. Consensus review from the May 2018 brainstem society meeting in Washington, DC, USA.
- Author
-
Garcia-Rill E, Saper CB, Rye DB, Kofler M, Nonnekes J, Lozano A, Valls-Solé J, and Hallett M
- Subjects
- Deep Brain Stimulation methods, District of Columbia epidemiology, Humans, Parkinson Disease physiopathology, Parkinson Disease therapy, Prepulse Inhibition physiology, Sleep Stages physiology, Brain Stem physiology, Congresses as Topic, Consensus, Pedunculopontine Tegmental Nucleus physiology, Societies, Medical
- Abstract
The pedunculopontine nucleus (PPN) is located in the mesopontine tegmentum and is best delimited by a group of large cholinergic neurons adjacent to the decussation of the superior cerebellar peduncle. This part of the brain, populated by many other neuronal groups, is a crossroads for many important functions. Good evidence relates the PPN to control of reflex reactions, sleep-wake cycles, posture and gait. However, the precise role of the PPN in all these functions has been controversial and there still are uncertainties in the functional anatomy and physiology of the nucleus. It is difficult to grasp the extent of the influence of the PPN, not only because of its varied functions and projections, but also because of the controversies arising from them. One controversy is its relationship to the mesencephalic locomotor region (MLR). In this regard, the PPN has become a new target for deep brain stimulation (DBS) for the treatment of parkinsonian gait disorders, including freezing of gait. This review is intended to indicate what is currently known, shed some light on the controversies that have arisen, and to provide a framework for future research., (Copyright © 2019. Published by Elsevier B.V.)
- Published
- 2019
- Full Text
- View/download PDF
29. Systemic exertion intolerance disease/chronic fatigue syndrome is common in sleep centre patients with hypersomnolence: A retrospective pilot study.
- Author
-
Maness C, Saini P, Bliwise DL, Olvera V, Rye DB, and Trotti LM
- Subjects
- Adult, Fatigue Syndrome, Chronic pathology, Female, Humans, Male, Middle Aged, Pilot Projects, Retrospective Studies, Surveys and Questionnaires, Disorders of Excessive Somnolence physiopathology, Fatigue Syndrome, Chronic etiology
- Abstract
Symptoms of the central disorders of hypersomnolence extend beyond excessive daytime sleepiness to include non-restorative sleep, fatigue and cognitive dysfunction. They share much in common with myalgic encephalomyelitis/chronic fatigue syndrome, recently renamed systemic exertion intolerance disease, whose additional features include post-exertional malaise and orthostatic intolerance. We sought to determine the frequency and correlates of systemic exertion intolerance disease in a hypersomnolent population. One-hundred and eighty-seven hypersomnolent patients completed questionnaires regarding sleepiness and fatigue; questionnaires and clinical records were used to assess for systemic exertion intolerance disease. Sleep studies, hypocretin and cataplexy were additionally used to assign diagnoses of hypersomnolence disorders or sleep apnea. Included diagnoses were idiopathic hypersomnia (n = 63), narcolepsy type 2 (n = 25), persistent sleepiness after obstructive sleep apnea treatment (n = 25), short habitual sleep duration (n = 41), and sleepiness with normal sleep study (n = 33). Twenty-one percent met systemic exertion intolerance disease criteria, and the frequency of systemic exertion intolerance disease was not different across sleep diagnoses (p = .37). Patients with systemic exertion intolerance disease were no different from those without this diagnosis by gender, age, Epworth Sleepiness Scale, depressive symptoms, or sleep study parameters. The whole cohort reported substantial fatigue on questionnaires, but the systemic exertion intolerance disease group exhibited more profound fatigue and was less likely to respond to traditional wake-promoting agents (88.6% versus 67.7%, p = .01). Systemic exertion intolerance disease appears to be a common co-morbidity in patients with hypersomnolence, which is not specific to hypersomnolence subtype but may portend a poorer prognosis for treatment response., (© 2018 European Sleep Research Society.)
- Published
- 2019
- Full Text
- View/download PDF
30. Inter-rater agreement for visual discrimination of phasic and tonic electromyographic activity in sleep.
- Author
-
Bliwise DL, Fairley J, Hoff S, Rosenberg RS, Rye DB, Schulman DA, and Trotti LM
- Subjects
- Humans, Judgment, Polysomnography methods, REM Sleep Behavior Disorder, Sleep, REM, Visual Perception, Electromyography methods, Observer Variation, Sleep, Sleep Medicine Specialty
- Abstract
Study Objectives: The objective of this study was to determine the confidence of expert raters in discriminating phasic and tonic electromyographic (EMG) activity. We undertook this study because we suspected that even expert scorers may disagree on whether a given EMG segment contained phasic activity, tonic activity, or both., Methods: Six individuals holding either Fellowship status in the American Academy of Sleep Medicine or Board Certification in Sleep Medicine with at least 5 years experience in interpreting polysomnography visually examined 60 segments containing EMG activity. Raters determined their relative confidence that each segment contained phasic and tonic activity by noting whether they were highly certain or somewhat certain that the segment contained such activity or somewhat certain or highly certain that each segment did not contain such activity. Every segment was rated by every rater twice, once for phasic and once for tonic activity., Results: Substantial differences among raters existed in certainty regarding presence/absence of both phasic and tonic activity, although raters agreed on segments far above chance. Consensus was higher on certainty regarding presence of phasic, relative to tonic, activity., Conclusions: These findings indicate the limitations of visual analyses for discriminating abnormal muscle activity during sleep. Conversely, when expert judgments are combined with digitized measurements of EMG activity in sleep (e.g. REM atonia index), some allowance must be made for the unique contribution of visual analyses to such judgments, most notably for short duration EMG signals. These results may have relevance for polysomnographic interpretation in suspected synucleinopathies.
- Published
- 2018
- Full Text
- View/download PDF
31. Postnatal hypoxia evokes persistent changes within the male rat's dopaminergic system.
- Author
-
Decker MJ, Jones KA, Keating GL, and Rye DB
- Subjects
- Amphetamine administration & dosage, Amphetamine pharmacology, Animals, Animals, Newborn, Male, Rats, Rats, Sprague-Dawley, Dopamine metabolism, Hypoxia metabolism
- Abstract
Purpose: Hypoxic insults occurring during the perinatal period remain the leading cause of permanent brain impairment. Severe cognitive and motor dysfunction, as seen in cerebral palsy, will occur in 4-10% of post-hypoxic newborns. Subtle cognitive impairment, apparent in disorders of minimal brain dysfunction will occur in > 3 million post-hypoxic newborns. Analyses of post-hypoxic rodent brains reveal reduced extracellular levels of dopamine, a key neurotransmitter of vigilance, execute function, and behavior. The purpose of this study was to assess whether synaptic levels of dopamine could be enhanced in post-hypoxic, hypodopaminergic rats., Methods: Newborn male rats were exposed to subtle, repetitive hypoxic insults for 4-6 h per day, during postnatal days 7-11. During adolescence, we quantified dopamine content within the caudate nuclei. We then determined whether extracellular dopamine levels could be increased by injecting the psychostimulant d-amphetamine. We next assessed whether the post-hypoxic rat's response to d-amphetamine would differentially impact place preference behavior when compared with littermate controls., Results: Total tissue content of dopamine was significantly higher in post-hypoxic rats. Injection of d-amphetamine liberated that dopamine which subsequently enhanced extracellular levels. Post-hypoxic rats acquired conditioned place preference for d-amphetamine during the training days. During the testing day, total time spent in the amphetamine-pairing box did not differ between post-hypoxic and control littermates., Conclusion: Postnatally occurring hypoxic insults promote remodeling of the dopaminergic system resulting in increased intracellular sequestering of this monoamine. That sequestered dopamine can be released using the psychostimulant d-amphetamine, which did not promote a conditioned place preference any greater than was observed in non-hypoxic littermate controls.
- Published
- 2018
- Full Text
- View/download PDF
32. Hypocretin measurement: shelf age of radioimmunoassay kit, but not freezer time, influences assay variability.
- Author
-
Keating G, Bliwise DL, Saini P, Rye DB, and Trotti LM
- Subjects
- Disorders of Excessive Somnolence cerebrospinal fluid, Disorders of Excessive Somnolence diagnosis, Disorders of Excessive Somnolence genetics, Disorders of Excessive Somnolence physiopathology, Freezing, Gene Expression, Humans, Idiopathic Hypersomnia cerebrospinal fluid, Idiopathic Hypersomnia diagnosis, Idiopathic Hypersomnia genetics, Idiopathic Hypersomnia physiopathology, Narcolepsy cerebrospinal fluid, Narcolepsy genetics, Narcolepsy physiopathology, Observer Variation, Orexins cerebrospinal fluid, Reproducibility of Results, Sleep Apnea Syndromes cerebrospinal fluid, Sleep Apnea Syndromes diagnosis, Sleep Apnea Syndromes genetics, Sleep Apnea Syndromes physiopathology, Time Factors, Narcolepsy diagnosis, Orexins genetics, Radioimmunoassay standards, Reagent Kits, Diagnostic standards
- Abstract
The hypothalamic peptide hypocretin 1 (orexin A) may be assayed in cerebrospinal fluid to diagnose narcolepsy type 1. This testing is not commercially available, and factors contributing to assay variability have not previously been comprehensively explored. In the present study, cerebrospinal fluid hypocretin concentrations were determined in duplicate in 155 patient samples, across a range of sleep disorders. Intra-assay variability of these measures was analyzed. Inter-assay correlation between samples tested at Emory and at Stanford was high (r = 0.79, p < 0.0001). Intra-assay correlation between samples tested in duplicate in our center was also high (r = 0.88, p < 0.0001); intra-assay variability, expressed as the difference between values as a percentage of the higher value, was low at 9.4% (SD = 7.9%). Although both time the sample spent in the freezer (r = 0.16, p = 0.04) and age of the kit used for assay (t = 3.64, p = 0.0004) were significant predictors of intra-kit variability in univariate analyses, only age of kit was significant in multivariate linear regression (F = 4.93, p = 0.03). Age of radioimmunoassay kit affects intra-kit variability of measured hypocretin values, such that kits closer to expiration exhibit significantly more variability.
- Published
- 2017
- Full Text
- View/download PDF
33. Rigor, reproducibility, and in vitro cerebrospinal fluid assays: The devil in the details.
- Author
-
Moody OA, Talwar S, Jenkins MA, Freeman AA, Trotti LM, García PS, Bliwise D, Lynch JW, Cherson B, Hernandez EM, Feldman N, Saini P, Rye DB, and Jenkins A
- Subjects
- Humans, Reproducibility of Results, Research Design, gamma-Aminobutyric Acid, Disorders of Excessive Somnolence, Receptors, GABA
- Published
- 2017
- Full Text
- View/download PDF
34. Genetics of restless legs syndrome.
- Author
-
Winkelmann J, Schormair B, Xiong L, Dion PA, Rye DB, and Rouleau GA
- Subjects
- Animals, Humans, Restless Legs Syndrome metabolism, Restless Legs Syndrome genetics
- Abstract
At the outset of genetic studies in restless legs syndrome (RLS), the disorder was assumed to be a classical monogenic disorder that runs in families. However, years of family studies did not reveal any causally-related genes or genetic variants. The advent of high-throughput genotyping technology led to a change; genome-wide association studies in large case-control samples became feasible, which led to the identification of first genetic risk variants for RLS. Variants detected by this approach are common ones, which that individually confer only a minor increase in risk of disease. Overall, the currently known risk variants in six genomic loci account for only a small proportion of the genetically determined susceptibility to RLS. Additional risk loci and individual variants remain to be discovered. First studies indicate that rare genetic variants are also important contributors in RLS. These are expected to have a larger impact on the phenotype and may thus prove to be excellent candidates for functional studies and, in the long-term, targets for developing therapeutics or preventive measures. To enable their discovery, large-scale studies including tens of thousands of affected individuals may be needed. Next-generation sequencing technologies such as whole exome or whole genome sequencing will be essential for this endeavor. Even though the number of known risk variants is still limited, they have been indispensable in terms of deciphering the underlying pathophysiology of RLS, providing the molecular starting points for animal models and in vitro studies to understand disease mechanisms. In addition, genetic risk variants can be valuable tools for disentangling the phenotypic complexity observed in RLS. Testing RLS risk variants for associations with periodic limb movements (PLMs) identified a significant role of some of the variants and suggested PLMs as an endophenotype in RLS. Further advances in genetics research in RLS will be driven by large-scale sequencing projects and the identification of additional common, but also rarer risk variants with larger effects on disease risk. Another uncharted territory in RLS research epigenetic effect on gene activity. Overall, genetic studies continue to hold great potential for understanding biology of the disease., (Copyright © 2016. Published by Elsevier B.V.)
- Published
- 2017
- Full Text
- View/download PDF
35. Hypersomnia: Evaluation, Treatment, and Social and Economic Aspects.
- Author
-
Saini P and Rye DB
- Subjects
- Disorders of Excessive Somnolence diagnosis, Disorders of Excessive Somnolence epidemiology, Humans, Hypnotics and Sedatives administration & dosage, Hypnotics and Sedatives adverse effects, Disorders of Excessive Somnolence economics, Disorders of Excessive Somnolence therapy
- Abstract
Most central disorders of hypersomnolence are conditions with poorly understood pathophysiologies, making their identification, treatment, and management challenging for sleep clinicians. The most challenging to diagnose and treat is idiopathic hypersomnia. There are no FDA-approved treatments, and off-label usage of narcolepsy treatments seldom provide benefit. Patients are largely left on their own to alleviate the compound effects of this disorder on their quality of life. This review covers the major points regarding clinical features and diagnosis of idiopathic hypersomnia, reviews current evidence supporting the available treatment options, and discusses the psychosocial impact and effects of idiopathic hypersomnia., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
36. Animal models of RLS phenotypes.
- Author
-
Allen RP, Donelson NC, Jones BC, Li Y, Manconi M, Rye DB, Sanyal S, and Winkelmann J
- Subjects
- Animals, Humans, Phenotype, Disease Models, Animal, Restless Legs Syndrome genetics, Restless Legs Syndrome physiopathology
- Abstract
Restless legs syndrome (RLS) is a complex disorder that involves sensory and motor systems. The major pathophysiology of RLS is low iron concentration in the substantia nigra containing the cell bodies of dopamine neurons that project to the striatum, an area that is crucial for modulating movement. People who have RLS often present with normal iron values outside the brain; recent studies implicate several genes are involved in the syndrome. Like most complex diseases, animal models usually do not faithfully capture the full phenotypic spectrum of "disease," which is a uniquely human construct. Nonetheless, animal models have proven useful in helping to unravel the complex pathophysiology of diseases such as RLS and suggesting novel treatment paradigms. For example, hypothesis-independent genome-wide association studies (GWAS) have identified several genes as increasing the risk for RLS, including BTBD9. Independently, the murine homolog Btbd9 was identified as a candidate gene for iron regulation in the midbrain in mice. The relevance of the phenotype of another of the GWAS identified genes, MEIS1, has also been explored. The role of Btbd9 in iron regulation and RLS-like behaviors has been further evaluated in mice carrying a null mutation of the gene and in fruit flies when the BTBD9 protein is degraded. The BTBD9 and MEIS1 stories originate from human GWAS research, supported by work in a genetic reference population of mice (forward genetics) and further verified in mice, fish flies, and worms. Finally, the role of genetics is further supported by an inbred mouse strain that displays many of the phenotypic characteristics of RLS. The role of animal models of RLS phenotypes is also extended to include periodic limb movements., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
37. In Reply.
- Author
-
Safavynia SA, Keating G, Speigel I, Fidler JA, Kreuzer M, Rye DB, Jenkins A, and García PS
- Published
- 2017
- Full Text
- View/download PDF
38. Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients.
- Author
-
Trotti LM, Saini P, Koola C, LaBarbera V, Bliwise DL, and Rye DB
- Subjects
- Adult, Female, Humans, Male, Retrospective Studies, Treatment Outcome, Disorders of Excessive Somnolence drug therapy, Flumazenil therapeutic use, GABA Modulators therapeutic use
- Abstract
Study Objectives: Patients with central disorders of hypersomnolence sometimes do not achieve satisfactory symptom control with currently available wake-promoting medications. Based on the finding that the cerebrospinal fluid from some patients with hypersomnolence demonstrates potentiation of gamma-aminobutyric acid (GABA)-A receptors in excess of that of controls, a finding that reverses with flumazenil, we initiated prescribing compounded flumazenil to carefully selected, treatment-refractory hypersomnolent patients., Methods: This retrospective chart review evaluated the first 153 consecutive patients treated with transdermal and/or sublingual flumazenil by physicians at our center from 2013 through January 2015., Results: Patients were 35.5 y old (± 14.4) and 92 (60.1%) were women. Mean Epworth Sleepiness Scale scores prior to flumazenil were 15.1 (± 4.5) despite prior or current treatment with traditional wake-promoting therapies. Symptomatic benefit was noted by 96 patients (62.8%), with a mean reduction in Epworth Sleepiness Scale score of 4.7 points (± 4.7) among responders. Of these, 59 remained on flumazenil chronically, for a mean of 7.8 mo (± 6.9 mo). Female sex and presence of reported sleep inertia differentiated flumazenil responders from nonresponders. Adverse events were common, but often did not result in treatment discontinuation. Serious adverse events included a transient ischemic attack and a lupus vasculopathy, although whether these events occurred because of flumazenil administration is unknown., Conclusions: This chart review demonstrates that sublingual and transdermal flumazenil provided sustained clinical benefit to 39% of patients with treatment-refractory hypersomnolence. Prospective, controlled studies of this GABA-A receptor antagonist for the treatment of hypersomnolence are needed., Commentary: A commentary on this article appears in this issue on page 1321., (© 2016 American Academy of Sleep Medicine)
- Published
- 2016
- Full Text
- View/download PDF
39. Effects of γ-Aminobutyric Acid Type A Receptor Modulation by Flumazenil on Emergence from General Anesthesia.
- Author
-
Safavynia SA, Keating G, Speigel I, Fidler JA, Kreuzer M, Rye DB, Jenkins A, and García PS
- Subjects
- Administration, Intravenous, Anesthesia, Inhalation, Anesthetics, Inhalation pharmacology, Animals, Arousal drug effects, Behavior, Animal drug effects, Electroencephalography drug effects, Electromyography drug effects, Flumazenil administration & dosage, GABA Modulators administration & dosage, HEK293 Cells, Humans, Isoflurane pharmacology, Male, Rats, Rats, Sprague-Dawley, Receptors, GABA-A biosynthesis, Receptors, GABA-A genetics, Sleep drug effects, Anesthesia Recovery Period, Flumazenil pharmacology, GABA Modulators pharmacology, Receptors, GABA-A drug effects
- Abstract
Background: Transitions into conscious states are partially mediated by inactivation of sleep networks and activation of arousal networks. Pharmacologic hastening of emergence from general anesthesia has largely focused on activating subcortical monoaminergic networks, with little attention on antagonizing the γ-aminobutyric acid type A receptor (GABAAR). As the GABAAR mediates the clinical effects of many common general anesthetics, the authors hypothesized that negative GABAAR modulators would hasten emergence, possibly via cortical networks involved in sleep., Methods: The authors investigated the capacity of the benzodiazepine rescue agent, flumazenil, which had been recently shown to promote wakefulness in hypersomnia patients, to alter emergence. Using an in vivo rodent model and an in vitro GABAAR heterologous expression system, they measured flumazenil's effects on behavioral, neurophysiologic, and electrophysiologic correlates of emergence from isoflurane anesthesia., Results: Animals administered intravenous flumazenil (0.4 mg/kg, n = 8) exhibited hastened emergence compared to saline-treated animals (n = 8) at cessation of isoflurane anesthesia. Wake-like electroencephalographic patterns occurred sooner and exhibited more high-frequency electroencephalography power after flumazenil administration (median latency ± median absolute deviation: 290 ± 34 s) compared to saline administration (473 ± 186 s; P = 0.042). Moreover, in flumazenil-treated animals, there was a decreased impact on postanesthesia sleep. In vitro experiments in human embryonic kidney-293T cells demonstrated that flumazenil inhibited isoflurane-mediated GABA current enhancement (n = 34 cells, 88.7 ± 2.42% potentiation at 3 μM). Moreover, flumazenil exhibited weak agonist activity on the GABAAR (n = 10 cells, 10.3 ± 3.96% peak GABA EC20 current at 1 μM)., Conclusions: Flumazenil can modulate emergence from isoflurane anesthesia. The authors highlight the complex role GABAARs play in mediating consciousness and provide mechanistic links between emergence from anesthesia and arousal.
- Published
- 2016
- Full Text
- View/download PDF
40. Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial.
- Author
-
Trotti LM, Saini P, Bliwise DL, Freeman AA, Jenkins A, and Rye DB
- Subjects
- Adult, Clarithromycin pharmacology, Cross-Over Studies, Disorders of Excessive Somnolence diagnosis, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychomotor Performance drug effects, Psychomotor Performance physiology, Reaction Time drug effects, Reaction Time physiology, Young Adult, Clarithromycin therapeutic use, Disorders of Excessive Somnolence cerebrospinal fluid, Disorders of Excessive Somnolence drug therapy, gamma-Aminobutyric Acid cerebrospinal fluid
- Abstract
Objective: Some central hypersomnolence syndromes are associated with a positive allosteric modulator of γ-aminobutyric acid (GABA)-A receptors in cerebrospinal fluid. Negative allosteric modulators of GABA-A receptors, including clarithromycin, have been reported to reduce sleepiness in these patients. We sought to systematically assess the effects of clarithromycin on objective vigilance and subjective sleepiness., Methods: This was a 5-week, randomized, placebo-controlled, double-blind, crossover trial of clarithromycin 500mg with breakfast and lunch, in patients with hypersomnolence syndromes (excluding narcolepsy with cataplexy) and evidence for abnormal cerebrospinal fluid potentiation of GABA-A receptors. The study occurred at a university-affiliated medical center. The primary outcome measure was median reaction time on the psychomotor vigilance task (PVT) at week 2 in each condition. Secondary outcomes included the Epworth Sleepiness Scale, Stanford Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, Pittsburgh Sleep Quality Index, SF-36, and additional PVT measures., Results: Twenty-three patients began treatment. Three patients dropped out, and final analyses were performed on 20 complete cases. Median reaction time was not significantly different between clarithromycin and placebo. Subjective measures of sleepiness were significantly improved on clarithromycin versus placebo. Altered taste perception occurred, but was the only side effect more common on clarithromycin than placebo. No serious adverse events occurred., Interpretation: Subjective sleepiness, but not psychomotor vigilance, improved during a 2-week course of clarithromycin. Although additional studies are needed, this suggests that clarithromycin may be a reasonable treatment option in patients with treatment-refractory hypersomnolence. This trial was registered at ClinicalTrials.gov (NCT01146600) and supported by the American Sleep Medicine Foundation., (© 2015 American Neurological Association.)
- Published
- 2015
- Full Text
- View/download PDF
41. The Molecular Genetics of Restless Legs Syndrome.
- Author
-
Rye DB
- Subjects
- Animals, Humans, Restless Legs Syndrome epidemiology, Restless Legs Syndrome genetics, Restless Legs Syndrome metabolism
- Abstract
Restless legs syndrome (RLS) is a common sensorimotor trait defined by symptoms that interfere with sleep onset and maintenance in a clinically meaningful way. Nonvolitional myoclonus while awake and asleep is a sign of the disorder and an informative endophenotype. The genetic contributions to RLS/periodic leg movements are substantial, are among the most robust defined to date for a common disease, and account for much of the variance in disease expressivity. The disorder is polygenic, as revealed by recent genome-wide association studies. Experimental studies are revealing mechanistic details of how these common variants might influence RLS expressivity., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
42. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.
- Author
-
Weinberger JF, Raison CL, Rye DB, Montague AR, Woolwine BJ, Felger JC, Haroon E, and Miller AH
- Subjects
- Adult, Depressive Disorder, Treatment-Resistant blood, Female, Humans, Inflammation blood, Male, Middle Aged, Receptors, Tumor Necrosis Factor, Type I blood, Receptors, Tumor Necrosis Factor, Type II blood, Sleep physiology, Tumor Necrosis Factor-alpha blood, Depressive Disorder, Treatment-Resistant physiopathology, Inflammation physiopathology, Infliximab pharmacology, Sleep drug effects, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Blockade of the inflammatory cytokine tumor necrosis factor (TNF) in depressed patients with increased inflammation has been associated with decreased depressive symptoms. Nevertheless, the impact of TNF blockade on sleep in depressed patients has not been examined. Accordingly, sleep parameters were measured using polysomnography in 36 patients with treatment resistant major depression at baseline and 2weeks after 3 infusions (week 8) of either the TNF antagonist infliximab (n=19) or placebo (n=17). Markers of inflammation including c-reactive protein (CRP) and TNF and its soluble receptors were also assessed along with depression measured by the 17-item Hamilton Depression Rating Scale. No differences in sleep parameters were found as a function of infliximab treatment over time. Nevertheless, wake after sleep onset (WASO), the spontaneous arousal index and sleep period time significantly decreased, and sleep efficiency significantly increased, from baseline to week 8 in infliximab-treated patients with high (CRP>5mg/L) (n=9) versus low inflammation (CRP⩽5mg/L) (n=10), controlling for changes in scores of depression. Stage 2 sleep also significantly decreased in infliximab-treated patients with high versus low inflammation. Decreases in soluble TNF receptor 1 (sTNFR1) significantly correlated with decreases in WASO and increases in sleep efficiency in infliximab-treated subjects with high inflammation. Placebo-treated subjects exhibited no sleep changes as a function of inflammation, and no correlations between inflammatory markers and sleep parameters in placebo-treated patients were found. These data suggest that inhibition of inflammation may be a viable strategy to improve sleep alterations in patients with depression and other disorders associated with increased inflammation., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
43. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience.
- Author
-
Trotti LM, Saini P, Freeman AA, Bliwise DL, García PS, Jenkins A, and Rye DB
- Subjects
- Adult, Clarithromycin adverse effects, Disorders of Excessive Somnolence cerebrospinal fluid, Disorders of Excessive Somnolence diagnosis, Disorders of Excessive Somnolence physiopathology, Female, HEK293 Cells, Humans, Male, Middle Aged, Psychomotor Performance drug effects, Receptors, GABA-A genetics, Retrospective Studies, Time Factors, Transfection, Treatment Outcome, Wakefulness-Promoting Agents adverse effects, Young Adult, Clarithromycin therapeutic use, Disorders of Excessive Somnolence drug therapy, Receptors, GABA-A metabolism, Sleep drug effects, Wakefulness drug effects, Wakefulness-Promoting Agents therapeutic use
- Abstract
The macrolide antibiotic clarithromycin can enhance central nervous system excitability, possibly by antagonism of GABA-A receptors. Enhancement of GABA signaling has recently been demonstrated in a significant proportion of patients with central nervous system hypersomnias, so we sought to determine whether clarithromycin might provide symptomatic benefit in these patients. We performed a retrospective review of all patients treated with clarithromycin for hypersomnia, in whom cerebrospinal fluid enhanced GABA-A receptor activity in vitro in excess of controls, excluding those with hypocretin deficiency or definite cataplexy. Subjective reports of benefit and objective measures of psychomotor vigilance were collected to assess clarithromycin's effects. Clinical and demographic characteristics were compared in responders and non-responders. In total, 53 patients (38 women, mean age 35.2 (SD 12.8 years)) were prescribed clarithromycin. Of these, 34 (64%) reported improvement in daytime sleepiness, while 10 (19%) did not tolerate its side effects, and nine (17%) found it tolerable but without symptomatic benefit. In those who reported subjective benefit, objective corroboration of improved vigilance was evident on the psychomotor vigilance task. Twenty patients (38%) elected to continue clarithromycin therapy. Clarithromycin responders were significantly younger than non-responders. Clarithromycin may be useful in the treatment of hypersomnia associated with enhancement of GABA-A receptor function. Further evaluation of this novel therapy is needed., (© The Author(s) 2013.)
- Published
- 2014
- Full Text
- View/download PDF
44. Wavelet analysis for detection of phasic electromyographic activity in sleep: influence of mother wavelet and dimensionality reduction.
- Author
-
Fairley JA, Georgoulas G, Smart OL, Dimakopoulos G, Karvelis P, Stylios CD, Rye DB, and Bliwise DL
- Subjects
- Algorithms, Databases, Factual, Humans, Principal Component Analysis, Electromyography methods, Polysomnography methods, Sleep Stages physiology, Wavelet Analysis
- Abstract
Phasic electromyographic (EMG) activity during sleep is characterized by brief muscle twitches (duration 100-500ms, amplitude four times background activity). High rates of such activity may have clinical relevance. This paper presents wavelet (WT) analyses to detect phasic EMG, examining both Symlet and Daubechies approaches. Feature extraction included 1s epoch processing with 24 WT-based features and dimensionality reduction involved comparing two techniques: principal component analysis and a feature/variable selection algorithm. Classification was conducted using a linear classifier. Valid automated detection was obtained in comparison to expert human judgment with high (>90%) classification performance for 11/12 datasets., (Published by Elsevier Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
45. Further experience using clarithromycin in patients with Kleine-Levin syndrome.
- Author
-
Trotti LM, Bliwise DL, and Rye DB
- Subjects
- Female, Humans, Clarithromycin therapeutic use, Kleine-Levin Syndrome drug therapy, Protein Synthesis Inhibitors therapeutic use
- Published
- 2014
- Full Text
- View/download PDF
46. The molecular basis of restless legs syndrome.
- Author
-
Freeman AA and Rye DB
- Subjects
- Animals, Brain physiopathology, Humans, Restless Legs Syndrome genetics, Restless Legs Syndrome physiopathology
- Abstract
Restless legs syndrome (RLS) disrupts sleep in a substantial proportion of the population and is associated with higher cross-sectional rates of affective illness and cardiovascular disease. While dopamine and iron availability in the brain modulate emergence of symptoms, and dopamine agonists and iron alleviate the sensory symptoms and motor signs of RLS, the biology of the disorder is incompletely understood. Genetic factors, as opposed to environmental ones, account for most of the disease variance. The at-risk allelic variants exist in non-coding regions of at least six genes rendering it a complex genetic disease. Nonetheless, these provide the first hypothesis independent clues that advance a better understanding of RLS pathophysiology., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
47. Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates.
- Author
-
Felger JC, Mun J, Kimmel HL, Nye JA, Drake DF, Hernandez CR, Freeman AA, Rye DB, Goodman MM, Howell LL, and Miller AH
- Subjects
- Amphetamine pharmacology, Animals, Carbon Radioisotopes, Corpus Striatum diagnostic imaging, Corpus Striatum drug effects, Dopamine Antagonists, Female, Fluorine Radioisotopes, Functional Neuroimaging, Macaca mulatta, Male, Nortropanes, Raclopride, Radioligand Assay, Radionuclide Imaging, Anhedonia drug effects, Corpus Striatum metabolism, Dopamine metabolism, Interferon-alpha pharmacology, Receptors, Dopamine D2 metabolism
- Abstract
Neuroimaging studies in humans have demonstrated that inflammatory cytokines target basal ganglia function and presynaptic dopamine (DA), leading to symptoms of depression. Cytokine-treated nonhuman primates also exhibit evidence of altered DA metabolism in association with depressive-like behaviors. To further examine cytokine effects on striatal DA function, eight rhesus monkeys (four male, four female) were administered interferon (IFN)-α (20 MIU/m(2) s.c.) or saline for 4 weeks. In vivo microdialysis was used to investigate IFN-α effects on DA release in the striatum. In addition, positron emission tomography (PET) with [(11)C]raclopride was used to examine IFN-α-induced changes in DA2 receptor (D2R) binding potential before and after intravenous amphetamine administration. DA transporter binding was measured by PET using [(18)F]2β-carbomethoxy-3β-(4-chlorophenyl)-8-(2-fluoroethyl)nortropane. Anhedonia-like behavior (sucrose consumption) was assessed during saline and IFN-α administration. In vivo microdialysis demonstrated decreased release of DA after 4 weeks of IFN-α administration compared with saline. PET neuroimaging also revealed decreased DA release after 4 weeks of IFN-α as evidenced by reduced displacement of [(11)C]raclopride following amphetamine administration. In addition, 4 weeks of IFN-α was associated with decreased D2R binding but no change in the DA transporter. Sucrose consumption was reduced during IFN-α administration and was correlated with decreased DA release at 4 weeks as measured by in vivo microdialysis. Taken together, these findings indicate that chronic peripheral IFN-α exposure reduces striatal DA release in association with anhedonia-like behavior in nonhuman primates. Future studies examining the mechanisms of cytokine effects on DA release and potential therapeutic strategies to reverse these changes are warranted.
- Published
- 2013
- Full Text
- View/download PDF
48. A prospective photographic study of the ocular fundus in obstructive sleep apnea.
- Author
-
Fraser CL, Bliwise DL, Newman NJ, Lamirel C, Collop NA, Rye DB, Trotti LM, Biousse V, and Bruce BB
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Papilledema complications, Papilledema physiopathology, Polysomnography, Prospective Studies, Sleep Apnea, Obstructive complications, Sleep Apnea, Obstructive diagnosis, Sleep Apnea, Obstructive physiopathology, Fundus Oculi, Papilledema diagnosis
- Abstract
Background: The prevalence of optic nerve and retinal vascular changes within the obstructive sleep apnea (OSA) population are not well-known, although it has been postulated that optic nerve ischemic changes and findings related to an elevated intracranial pressure may be more common in OSA patients. We prospectively evaluated the ocular fundus in unselected patients undergoing overnight diagnostic polysomnography (PSG)., Methods: Demographic data, medical/ocular history, and nonmydriatic fundus photographs were prospectively collected in patients undergoing PSG at our institution and reviewed for the presence of optic disc edema for which our study was appropriately powered a priori. Retinal vascular changes were also evaluated. OSA was defined using the measures of both sleep-disordered breathing and hypoxia., Results: Of 250 patients evaluated in the sleep center, fundus photographs were performed on 215 patients, among whom 127 patients (59%) had an apnea/hypopnea index (AHI) ≥ 15 events per hour, including 36 with severe OSA. Those with AHI <15 served as the comparison group. None of the patients had optic disc edema (95% confidence interval [CI]: 0%-3%). There was no difference in rates of glaucomatous appearance or pallor of the optic disc among the groups. Retinal arteriolar changes were more common in severe OSA patients (odds ratio: 1.09 per 5 unit increase in AHI; 95% CI, 1.02-1.16; P = 0.01), even after controlling for mean arterial blood pressure., Conclusions: We did not find an increased prevalence of optic disc edema or other optic neuropathies in our OSA population. However, retinal vascular changes were more common in patients with severe OSA, independent of blood pressure.
- Published
- 2013
- Full Text
- View/download PDF
49. Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia.
- Author
-
Trotti LM, Staab BA, and Rye DB
- Subjects
- Adult, Cataplexy, Cohort Studies, Diagnosis, Differential, Female, Humans, Male, Polysomnography, Reproducibility of Results, Disorders of Excessive Somnolence diagnosis, Narcolepsy diagnosis
- Abstract
Study Objectives: Differentiation of narcolepsy without cataplexy from idiopathic hypersomnia relies entirely upon the multiple sleep latency test (MSLT). However, the test-retest reliability for these central nervous system hypersomnias has never been determined., Methods: Patients with narcolepsy without cataplexy, idiopathic hypersomnia, and physiologic hypersomnia who underwent two diagnostic multiple sleep latency tests were identified retrospectively. Correlations between the mean sleep latencies on the two studies were evaluated, and we probed for demographic and clinical features associated with reproducibility versus change in diagnosis., Results: Thirty-six patients (58% women, mean age 34 years) were included. Inter -test interval was 4.2 ± 3.8 years (range 2.5 months to 16.9 years). Mean sleep latencies on the first and second tests were 5.5 (± 3.7 SD) and 7.3 (± 3.9) minutes, respectively, with no significant correlation (r = 0.17, p = 0.31). A change in diagnosis occurred in 53% of patients, and was accounted for by a difference in the mean sleep latency (N = 15, 42%) or the number of sleep onset REM periods (N = 11, 31%). The only feature predictive of a diagnosis change was a history of hypnagogic or hypnopompic hallucinations., Conclusions: The multiple sleep latency test demonstrates poor test-retest reliability in a clinical population of patients with central nervous system hypersomnia evaluated in a tertiary referral center. Alternative diagnostic tools are needed.
- Published
- 2013
- Full Text
- View/download PDF
50. Restless legs syndrome, pica, and iron status in blood donors.
- Author
-
Spencer BR, Kleinman S, Wright DJ, Glynn SA, Rye DB, Kiss JE, Mast AE, and Cable RG
- Subjects
- Adult, Aged, Aged, 80 and over, Anemia, Iron-Deficiency diagnosis, Female, Follow-Up Studies, Humans, Logistic Models, Male, Middle Aged, Odds Ratio, Pica diagnosis, Pica epidemiology, Prevalence, Prospective Studies, Restless Legs Syndrome diagnosis, Restless Legs Syndrome epidemiology, Risk Factors, Self Report, Anemia, Iron-Deficiency complications, Blood Donors, Pica etiology, Restless Legs Syndrome etiology
- Abstract
Background: The association of blood donation-related iron deficiency with pica or restless legs syndrome (RLS) remains poorly elucidated. This study evaluated the prevalence of RLS and pica in blood donors completing the REDS-II Iron Status Evaluation (RISE) study., Study Design and Methods: RISE enrolled 2425 blood donors in a prospective cohort study; 1334 donors provided blood samples to characterize iron status and answered a questionnaire inquiring into symptoms of RLS and pica at a final visit after 15 to 24 months of follow-up. Associations between both conditions and iron status were evaluated., Results: There were 9 and 20% of donors reporting symptoms of probable or probable/possible RLS, respectively. Iron depletion and donation intensity were not predictive of RLS. Pica was reported by 65 donors (5.5%), half of whom reported daily cravings. Prevalence of pica increased with degree of iron depletion in women (2% in iron-replete females, 13% in those with ferritin < 12 ng/mL), but not in men. Probable RLS and pica coexpressed in eight individuals, but no more frequently than expected by chance., Conclusion: RLS and pica have been associated with iron deficiency in nondonor populations. This study indicates a potentially high prevalence of RLS in frequent blood donors but shows no association with iron status or donation intensity. Low iron stores were associated with higher prevalence of pica, but only in females. Furthermore, the results are incompatible with RLS and pica sharing a common pathophysiology., (© 2013 American Association of Blood Banks.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.